Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part I - 'The pros'

Hormone and Metabolic Research

Volumn 28, Issue 9, 1996, Pages 517-521

  Waldhausl W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLUCOSE; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

CONFERENCE PAPER; GLUCOSE METABOLISM; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0029852412     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979844     Document Type: Conference Paper

References (42)

1. Alberti, K. G. M. M., F. A. Gries, J. Jervell, H. M. J. Krans for European NIDDM Policy Group: A Desktop Guide for the management of non insulin dependent diabetes mellitus (NIDDM): An update. Diabetic Medicine II: 899-909 (1994)
2. Beck-Nielsen, H., O. Hother-Nielsen, A. Vag, F. Alford: Pathogenesis of Type 2 (non-insulin-dependent) diabetes mellitus: The role of skeletal muscle glucose uptake and hepatic glucose production in the development of hyperglycemia. A critical comment. Diabetologia 37: 217-221 (1994)
3. Chalmers, T. C.: Type II diabetes - insulin versus oral agents. N. Engl. J. Med. 315: 1233-1234 (1986)
4. DeFronzo, F. A.: The triumvirate β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37: 667-687 (1988)
5. Efendic, S., F. Enzmann, A. Nylén, K. Uvnäs-Wallensten, R. Luft: Effect of glucose/sulfonylurea interaction on release of insulin, glucagon and somatostatin from isolated perfused rat pancreas. Proc. Natl. Acad. Sci. USA 76: 5901-5904 (1979)
6. Falco, J. M., J. H. Parr, R. N. Simpon, V. Wynn: Lipoprotein analyses in varying degrees of glucose tolerance: comparison between non insulin dependent diabetic, impaired glucose tolerant, and control populations. Am. J. Med. 83: 641-647 (1987)
7. Fasching, P., K. Ratheiser, P. Nowotny, S. Kurzemann, S. Parzer, W. Waldhäusl: Insulin production following i.v. glucose, arginine and valine: different pattern in patients with impaired glucose tolerance and in NIDDM. Metabolism 43: 385-389 (1994)
8. Fasching, P., K. Ratheiser, D. Damjancic, B. Schneider, P. Nowotny, H. Vierhypper, W. Waldhäusl: Acute and chronic near-normoglycaemia are required to improve insulin resistance in insulin-dependent (Type 1) diabetes. Diabetologia 36: 346-351 (1993)
9. Feldmann, H. I., B. L. Strom: Utilization of drugs for diabetes mellitus. Pharmacoepidemiology. Drug safety 6: 220-229 (1991)
10. Ghosh, S., N. J. Schork: Genetic analysis of NIDDM. The study of quantitative traits. Diabetes 45: 1-14 (1996)
11. Grodsky, G. M., G. H. Epstein, R. Fanska, J. H. Karam: Pancreatic actions of sulfonylureas. Fed. Proc. 36: 2714-2719 (1977)
12. Groop, L., L. Luzi, A. Melander, P. H. Groop, K. Ratheiser, D. C. Simonson, R. A. DeFronzo: Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 36: 1320-1328 (1987)
13. Groop, L., P. H. Groop, S. Steuman, C. Saloranta, K. J. Totterman, F. Fyhrquist, A. Melander: Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 10: 671-678 (1987)
14. Hother-Nielsen, O., H. Beck-Nielsen: On the determination of basal glucose production rate in patients with type 2 (non-insulin dependent) diabetes using primed-continuous 3-3H-glucose infusion. Diabetologia 33: 603-610 (1990)
15. Hosker, J. P., A. S. Rudenski, M. A. Burnett, D. R. Matthews, R. C. Turner: Similar reduction of first and second phase B-cell responses at three different glucose levels in type 2 diabetes and the effect of glyclazide therapy. Metabolism 38: 767-772 (1989)
16. Jennings, A. M., R. M. Wilson, J. D. Ward: Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 12: 203-208 (1989)
17. Kilo, C., J. P. Miller, J. R. Williamson: The achilles heel of the University Group Diabetes Program. JAMA 243: 450-457 (1979)
18. Kolterman, O. G.: Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type 2 diabetes mellitus. Am. J. Med. 79: 23-33 (1985)
19. Mandarino, L. J., J. E. Gerich: Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non insulin dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues. Diabetes Care 7 (Suppl. 1): 89-99 (1984)
20. Matthews, D. R., J. P. Hosker, I. Stratton: The physiological action of gliclazide: β-cell function and insulin resistance. Diab. Res. Clin. Pract. 14: 553-560 (1991)
21. McCarthy, S. T., F. Harris, R. C. Turner: Glucose control of basal insulin secretion in diabetes. Diabetologia 13: 93-97 (1977)
22. Melander, A., P. O. Bitzén, O. Faber, L. Groop: Sulfonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use. Drugs 37: 58-72 (1989)
23. Noma, A., T. Shibasaki: Membrane current through adenosine-tripohosphate-regulated potassium channels in Guinea-pig ventricular cells. J. Physiol. 363: 463-480 (1985)
24. Olczak, S. A., R. H. Greenwood, C. N. Hales: The effect of glibenclamide administration on insulin sensitivity and insulin binding to monocytes in normal subjects. Diabetic Med. 2: 352-354 (1985)
25. O'Rahilly, S., R. C. Turner, D. R. Matthews: Impaired pulsatile secretion of insulin in relatives of patients with non insulin dependent diabetes. N. Engl. J. Med. 318: 1225-1230 (1988)
26. Ozaki, Y., Y. Yatomi, S. Kume: Effects of oral hypoglycemic agents on platelet functions. Biochem. Pharmacol. 44: 687-691 (1992)
27. Panzram, G., R. Zabel-Langhenning: Prognosis of diabetes mellitus in a geographically defined population. Diabetologia 20: 587-591 (1981)
28. Pek, S., S. S. Fajans, J. C. Floyd Jr., R. F. Knopf, J. W. Conn: Failure of sulfonylureas to suppress plasma glucagon in man. Diabetes 21: 216-223 (1972)
29. Pfeifer, M. A., J. B. Halter, R. Graf, D. Porte: Potentiation of insulin secretion to nonglucose stimuli in normal man by tolbutamide. Diabetes 29: 335-340 (1980)
30. Ratheiser, K., A. Korn, W. Waldhäusl, M. Komjati, H. Vierhapper, M. Badian, V. Malerczyk: Dose relationship of stimulated insulin production following intravenous administration of glimepiride in healthy man. Drug Research 43: 856-858 (1993)
31. Reaven, G. M.: Role of insulin resistance in human disease. Diabetes 37: 1595-1607 (1988)
32. Reaven, C., J. Dray: Effect of chlorpropamide on serum glucose and immunoreactive insulin concentrations in patients with maternity onset diabetes mellitus. Diabetes 16: 487-492 (1967)
33. Samols, E., J. M. Tyler, P. Mialhe: Suppression of pancreatic glucagon release by the hypoglycemic sulfonylureas. Lancet I: 174-176 (1969)
34. Shapiro, E. T., E. van Cauter, H. Tillil, B. D. Given, L. Hirsch, C. Beebe, A. H. Rubenstein, K. S. Polonsky: Glyburide enhances the responsiveness of the b-cell to glucose but does not correct the abnormal patterns of insulin secretion in non insulin-dependent diabetes mellitus. J. Clin. Endorinol. Metab. 69: 571-576 (1989)
35. Skillman, T. G., J. M. Feldman: The pharmacology of sulfonylurea. Am. J. Med. 70: 361-372 (1981)
36. Sturgess, N. C., M. L. J. Ashford, D. L. Cook, C. N. Hales: The sulfonylurea receptor may be an ATP-sensitive potassium channel. Lancet II: 474-475 (1985)
37. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin dependent diabetes mellitus. N. Engl. J. Med. 329: 977-986 (1993)
38. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulfonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Brit. Med. J. 310: 83-88 (1995)
39. University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes. Diabetes 19 (Suppl. 2): 747-830 (1970)
40. Vaag, A., P. Damsbo, O. Hother-Nielsen, H. Beck-Nielsen: Hyperglycemia compensates for the defects in insulin mediated glucose metabolism and in the activation of glycogen synthase in the skeletal muscle of patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35: 80-88 (1992)
41. Waldhäusl, W., P. Bratusch-Marrain, S. Gasic, A. Korn, P. Nowotny: Insulin production rate, hepatic insulin retention and splanchnic carbohydrate metabolism after oral glucose ingestion in hyperinsulinemic type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 23: 6-15 (1982)
42. Waldhäusl, W.: Rational treatment of non-insulin dependent diabetes mellitus: Does it exist? Diab. Nutr. Metab. 4: 259-265 (1990)